PortalPublikationenTarget range maximum of cyclosporine blood concentration two...

Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients

Standard

Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients. / Dahmen, Uta; Beckebaum, S; Cicinnati, V; Valentin-Gamazo, C; Frilling, A; Malago, M; Broelsch, C E.

in: EUR J MED RES, Jahrgang 11, Nr. 4, 28.04.2006, S. 139-45.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Dahmen, U, Beckebaum, S, Cicinnati, V, Valentin-Gamazo, C, Frilling, A, Malago, M & Broelsch, CE 2006, 'Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients', EUR J MED RES, Jg. 11, Nr. 4, S. 139-45.

APA

Dahmen, U., Beckebaum, S., Cicinnati, V., Valentin-Gamazo, C., Frilling, A., Malago, M., & Broelsch, C. E. (2006). Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients. EUR J MED RES, 11(4), 139-45.

Vancouver

Dahmen U, Beckebaum S, Cicinnati V, Valentin-Gamazo C, Frilling A, Malago M et al. Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients. EUR J MED RES. 2006 Apr 28;11(4):139-45.

Bibtex

@article{51c693ce2a574f60be2300c8931700ae,
title = "Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients",
abstract = "Recently, single blood level measurement 2 hours after cyclosporine administration (C2) is taken as a more sensitive indicator of drug exposure in de novo transplant recipients than trough levels (C0). However, few studies focused on the determination of the C2 target range maximum and its associated adverse events in stable liver recipients. This prospective study was designed to assess the relative risk of developing CsA related side effects in patients with high C2-levels. Adverse effects were determined clinically, and by using a specially designed questionnaire. Eventual adverse events as well as C2 levels were determined repeatedly up to 4 times in 3-months intervals (observation period 9 +/- 3 months) in 36 long-term liver recipients (1-13.5 years post-transplant), in addition to conventional C0 levels. Cyclosporine dose was adjusted according to a predefined C0 target level range and clinical status. Totally 103 questionnaires and the corresponding paired CsA blood level records were obtained. C0 levels and C2 levels ranged from 90 to 287 (143 +/- 31) ng/ml and from 212 to 1358 (672 +/- 203) ng/ml respectively. No patient experienced a rejection episode during the observation period, demonstrating the efficiency of the immunosuppressive therapy. However, 33/36 patients (91%) showed symptoms attributable to CsA therapy. C2 levels above 750 ng/ml, determined at least twice in an interval of 3 months, were identified as a relevant risk factor for the presence of multiple adverse effects, which were defined as the combination of hypertension, renal insufficiency and more than two neurological complaints (RR = 3.11, p<0.01). This risk population was not completely identified by determination of C0 level.",
keywords = "Adult, Aged, Cyclosporine, Dose-Response Relationship, Drug, Drug Monitoring, Female, Humans, Immunosuppressive Agents, Liver Transplantation, Male, Middle Aged, Prospective Studies, Time Factors, Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't",
author = "Uta Dahmen and S Beckebaum and V Cicinnati and C Valentin-Gamazo and A Frilling and M Malago and Broelsch, {C E}",
year = "2006",
month = apr,
day = "28",
language = "English",
volume = "11",
pages = "139--45",
journal = "EUR J MED RES",
issn = "0949-2321",
publisher = "BioMed Central Ltd.",
number = "4",

}

RIS

TY - JOUR

T1 - Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients

AU - Dahmen, Uta

AU - Beckebaum, S

AU - Cicinnati, V

AU - Valentin-Gamazo, C

AU - Frilling, A

AU - Malago, M

AU - Broelsch, C E

PY - 2006/4/28

Y1 - 2006/4/28

N2 - Recently, single blood level measurement 2 hours after cyclosporine administration (C2) is taken as a more sensitive indicator of drug exposure in de novo transplant recipients than trough levels (C0). However, few studies focused on the determination of the C2 target range maximum and its associated adverse events in stable liver recipients. This prospective study was designed to assess the relative risk of developing CsA related side effects in patients with high C2-levels. Adverse effects were determined clinically, and by using a specially designed questionnaire. Eventual adverse events as well as C2 levels were determined repeatedly up to 4 times in 3-months intervals (observation period 9 +/- 3 months) in 36 long-term liver recipients (1-13.5 years post-transplant), in addition to conventional C0 levels. Cyclosporine dose was adjusted according to a predefined C0 target level range and clinical status. Totally 103 questionnaires and the corresponding paired CsA blood level records were obtained. C0 levels and C2 levels ranged from 90 to 287 (143 +/- 31) ng/ml and from 212 to 1358 (672 +/- 203) ng/ml respectively. No patient experienced a rejection episode during the observation period, demonstrating the efficiency of the immunosuppressive therapy. However, 33/36 patients (91%) showed symptoms attributable to CsA therapy. C2 levels above 750 ng/ml, determined at least twice in an interval of 3 months, were identified as a relevant risk factor for the presence of multiple adverse effects, which were defined as the combination of hypertension, renal insufficiency and more than two neurological complaints (RR = 3.11, p<0.01). This risk population was not completely identified by determination of C0 level.

AB - Recently, single blood level measurement 2 hours after cyclosporine administration (C2) is taken as a more sensitive indicator of drug exposure in de novo transplant recipients than trough levels (C0). However, few studies focused on the determination of the C2 target range maximum and its associated adverse events in stable liver recipients. This prospective study was designed to assess the relative risk of developing CsA related side effects in patients with high C2-levels. Adverse effects were determined clinically, and by using a specially designed questionnaire. Eventual adverse events as well as C2 levels were determined repeatedly up to 4 times in 3-months intervals (observation period 9 +/- 3 months) in 36 long-term liver recipients (1-13.5 years post-transplant), in addition to conventional C0 levels. Cyclosporine dose was adjusted according to a predefined C0 target level range and clinical status. Totally 103 questionnaires and the corresponding paired CsA blood level records were obtained. C0 levels and C2 levels ranged from 90 to 287 (143 +/- 31) ng/ml and from 212 to 1358 (672 +/- 203) ng/ml respectively. No patient experienced a rejection episode during the observation period, demonstrating the efficiency of the immunosuppressive therapy. However, 33/36 patients (91%) showed symptoms attributable to CsA therapy. C2 levels above 750 ng/ml, determined at least twice in an interval of 3 months, were identified as a relevant risk factor for the presence of multiple adverse effects, which were defined as the combination of hypertension, renal insufficiency and more than two neurological complaints (RR = 3.11, p<0.01). This risk population was not completely identified by determination of C0 level.

KW - Adult

KW - Aged

KW - Cyclosporine

KW - Dose-Response Relationship, Drug

KW - Drug Monitoring

KW - Female

KW - Humans

KW - Immunosuppressive Agents

KW - Liver Transplantation

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Time Factors

KW - Clinical Trial

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

M3 - SCORING: Journal article

C2 - 16720277

VL - 11

SP - 139

EP - 145

JO - EUR J MED RES

JF - EUR J MED RES

SN - 0949-2321

IS - 4

ER -